Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 5Recruiting 4Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoid Tumor 2Pinealoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroma, Acoustic 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms, Neuroepithelial 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

telotristat ethyl 3lutetium Lu 177 dotatate 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1gallium Ga 68 dotatate 1Tretinoin 1Temozolomide 1Isotretinoin 1Introns 1Everolimus 1Capecitabine 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroendocrine Tumors × gallium Ga 68 dotatate × Clear all
NCT03623984 2023-09-11

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

University of Alabama at Birmingham

Phase EARLY_PHASE1 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡